Kane will advance strategic priorities and advance Solrikitug, its lead asset, in Phase II trials and prepare for Phase III.

Incyte shares rose Thursday after the drugmaker named Bill Meury its new CEO, effective immediately, to replace the retiring Hervé Hoppenot.

The United States market has been flat over the last week but is up 13% over the past year, with earnings forecast to grow by 15% annually. In this environment, identifying high-growth tech stocks can ...

Bristol Myers Squibb is undervalued despite challenges. Learn how BMY stock's strong pipeline, cash flow, and growth ...

Bristol-Myers Squibb has decided to gamble on the FDA approving Karuna Therapeutics’ schizophrenia drug candidate KarXT next year, agreeing to buy the company for approximately $14 billion. The ...

Incyte named former Karuna Therapeutics and Anthos Therapeutics exec Bill Meury as CEO. Vistagen appoints Elissa Cote as chief corporate development officer. Inizio Evoke, a 2025 MM+M Agency 100 ...

Mr. Meury joined Anthos after leading Karuna Therapeutics, a biopharmaceutical company focused on neuroscience, until its merger with Bristol Meyers Squibb in March 2024.

Welcome to this week's Chutes & Ladders, our roundup | Incyte’s Hervé Hoppenot is hanging up his hat after spending more than a decade building the company into the multibillion-dollar ...

The team that brought you Karuna, recently sold to Bristol-Myers Squibb for $14 billion, has set up a neuropsychiatry-focused biotech called Seaport Therapeutics.